FDA's Mifepristone Rules Under Fire in Lawsuit
The lawsuit argues the FDA failed to re-evaluate mifepristone since 2000 and relaxed rules like removing in-person dispensing, violating the Administrative Procedure Act.
Over 100 studies show mifepristone is a reliable, low-risk abortion method used in 60% of U.S. medication abortions.
Evita Solutions supports abortion care access on its website.
The DOJ will defend the FDA, with appeals to the 5th Circuit Court of Appeals, naming HHS and agency leaders.
The Supreme Court dismissed a 2022 suit for lack of standing, while Missouri, Kansas, and Idaho pursued similar claims.
HHS Secretary Robert F. Kennedy Jr. delayed a safety report until next year.
1 month ago